B. Riley FBR analyst David Buck lowered his price target for Mallinckrodt to $21 after the company earlier this month announced plans to spin off a new company consisting of its specialty generics business and Amitiza to shareholders. The analyst keeps a Neutral rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.